IDE Gene Expression Screening for Early Skin Aging Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for specific biomarkers to detect early signs of skin aging, particularly when they are not yet visible, to effectively target and address these signs in a subject.
Innovation Solution
A diagnostic method involving the measurement of the expression level of the insulin-degrading enzyme (IDE) gene in a skin sample, preferably using non-invasive techniques, to identify and treat signs of aging such as elastosis, crow's feet wrinkles, and wrinkles under the eyes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional visual assessment methods are used to detect skin aging, then the detection process is simple and non-invasive, but the detection precision is insufficient for early-stage aging signs that are not yet visible
Solution Approach 1:
The patent replaces visual assessment (mechanical/optical observation) with molecular biomarker detection (chemical/biological measurement). By measuring IDE gene expression levels in skin samples, the method achieves early detection of aging signs before they become visually apparent, thereby improving measurement precision without requiring complex imaging equipment.
Solution Approach 2:
The patent introduces IDE (insulin-degrading enzyme) gene expression as an intermediary biomarker between actual skin aging processes and visible aging signs. This intermediary allows indirect detection of aging at the molecular level, enabling early detection without directly observing the aging signs themselves.
2Loss of time
If biomarkers are sought to detect early invisible signs of aging, then detection timing is improved, but the reliability of the biomarker must be validated against visible aging signs
Solution Approach 1:
The patent establishes a feedback loop where IDE gene expression levels are measured in skin samples, and the results are correlated with visible aging signs to validate the biomarker. This feedback mechanism confirms that elevated IDE expression reliably predicts visible aging signs, ensuring temporal precedence while maintaining reliability.
Solution Approach 2:
The patent performs preliminary measurement of IDE gene expression before visible aging signs appear. By detecting elevated IDE expression in advance, the method enables early intervention while the correlation with future visible signs is established through longitudinal validation, ensuring both time advantage and reliability.
3Measurement precision
If skin samples are taken for biomarker analysis, then detection accuracy is improved, but the procedure becomes more invasive
Solution Approach 1:
The patent applies local quality by using targeted skin sampling from specific areas (such as the face) where aging signs are most prominent. This localized approach maintains high detection accuracy while minimizing the invasiveness and extent of sampling compared to full-body biopsies.
Solution Approach 2:
The patent uses non-invasive or minimally invasive skin sampling methods (such as scrape tests or adhesive tape stripping) that create a copy of the skin surface for analysis without requiring deep tissue biopsies. This copying approach maintains sufficient biomarker detection accuracy while significantly reducing invasiveness.
Data Source
AI summary
This invention related to a method for diagnosing a skin displaying signs of aging, based on measuring the level of expression of the gene encoding the IDE. The present invention also relates to a method for the cosmetic treatment of skin. This invention also relates to a method for identifying a compound for reducing the signs of the aging of the skin as well as a kit.